GLUCOPHAGE Drug Patent Profile

« Back to Dashboard

Which patents cover Glucophage, and what generic alternatives are available?

Glucophage is a drug marketed by Emd Serono Inc and is included in two NDAs.

The generic ingredient in GLUCOPHAGE is metformin hydrochloride. There is one drug master file entry for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glucophage

A generic version of GLUCOPHAGE was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for GLUCOPHAGE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	352
Patent Applications:	38
Drug Prices:	Drug price information for GLUCOPHAGE
What excipients (inactive ingredients) are in GLUCOPHAGE?	GLUCOPHAGE excipients list
DailyMed Link:	GLUCOPHAGE at DailyMed

See drug prices for GLUCOPHAGE

See drug sales revenues for GLUCOPHAGE

Recent Clinical Trials for GLUCOPHAGE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China National Center for Cardiovascular Diseases	PHASE4
United States Department of Defense	Phase 1
James Wang	Phase 1

See all GLUCOPHAGE clinical trials

US Patents and Regulatory Information for GLUCOPHAGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	GLUCOPHAGE	metformin hydrochloride	TABLET;ORAL	020357-005	Nov 5, 1998		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE	metformin hydrochloride	TABLET;ORAL	020357-004	Nov 5, 1998		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE	metformin hydrochloride	TABLET;ORAL	020357-001	Mar 3, 1995		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE	metformin hydrochloride	TABLET;ORAL	020357-003	Nov 5, 1998		DISCN	Yes	No

GLUCOPHAGE Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: August 2, 2026

Glucophage is the original branded formulation of metformin, an oral biguanide used primarily for type 2 diabetes. Its commercial value has shifted from a patented brand to a mature, low-cost generic platform. Bristol-Myers Squibb historically commercialized Glucophage in the United States, while Merck and regional licensees marketed related products in other jurisdictions. The active ingredient, metformin hydrochloride, is now supplied by numerous generic manufacturers.

Glucophage no longer has meaningful product-level exclusivity in the United States. Its financial trajectory is therefore tied to generic metformin volumes, branded residual sales, extended-release formulations, combination products, and continued clinical use rather than patent pricing power.

What is Glucophage and how is it used?

Glucophage is an immediate-release metformin hydrochloride tablet. Glucophage XR is the extended-release version. Both are prescription medicines indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients with type 2 diabetes, subject to product labeling.

Product	Active ingredient	Formulation	Primary indication	Commercial status
Glucophage	Metformin hydrochloride	Immediate-release tablet	Type 2 diabetes	Mature branded product; generic competition
Glucophage XR	Metformin hydrochloride	Extended-release tablet	Type 2 diabetes	Mature branded product; generic competition
Generic metformin	Metformin hydrochloride	Immediate-release and extended-release tablets	Type 2 diabetes	Broad generic supply
Metformin oral solution and ER tablets	Metformin hydrochloride	Liquid or modified-release dosage forms	Type 2 diabetes	Selected generic and branded-generic products

Metformin reduces hepatic glucose production and improves insulin sensitivity. It remains a standard first-line therapy in many treatment guidelines because of its low cost, long clinical history, weight-neutral profile, and relatively favorable hypoglycemia risk when used without insulin or insulin secretagogues.[1]

How large is the Glucophage and metformin market?

The relevant commercial market is generic metformin, not the legacy Glucophage brand alone. Public company filings generally do not disclose Glucophage revenue as a separate line item, and metformin sales are often combined with broader diabetes portfolios.

Metformin has high prescription volume but low revenue per prescription. Its economic profile has four characteristics:

1. High patient penetration.
2. Low average selling prices.
3. Many approved manufacturers.
4. Limited ability to sustain premium branded pricing.

The United States, Europe, India, China, Japan, and Latin America account for substantial metformin use. Volume growth is supported by the global expansion of type 2 diabetes, while revenue growth is constrained by generic price competition.

The International Diabetes Federation estimated that approximately 537 million adults aged 20 to 79 were living with diabetes globally in 2021, with the total projected to rise to 643 million by 2030.[2] That epidemiological growth supports metformin demand, but it does not translate proportionally into Glucophage revenue because most new prescriptions are filled with generic products.

What drives metformin demand?

Demand is shaped by:

• Rising prevalence of type 2 diabetes.
• Primary-care prescribing.
• Public reimbursement and formulary placement.
• Low out-of-pocket cost.
• Use in combination with insulin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.
• Continued use in patients who cannot access or tolerate newer agents.

Metformin faces competitive pressure from newer therapies with stronger cardiovascular, renal, and weight-loss outcomes. SGLT2 inhibitors and GLP-1 receptor agonists have captured a growing share of diabetes spending, but they have not displaced metformin across the entire patient population because of cost, access, injection burden, and treatment sequencing.

When did Glucophage lose exclusivity?

Glucophage lost meaningful U.S. market exclusivity decades ago. The original immediate-release product was approved in the United States in 1994, with commercial launch following in 1995. Generic metformin entered the U.S. market after the expiration or resolution of the relevant exclusivity and patent barriers.

Glucophage XR was approved by the FDA in 2000. Extended-release metformin later became subject to generic competition, including products approved through abbreviated new drug applications. The FDA Orange Book does not provide a current basis for treating Glucophage as a protected, single-source U.S. product.[3]

Milestone	Approximate timing	Commercial effect
U.S. approval of immediate-release Glucophage	1994	Established branded U.S. product
U.S. commercial launch	1995	Initiated U.S. brand sales
Glucophage XR approval	2000	Added extended-release formulation
Generic immediate-release metformin	1990s	Began erosion of branded share
Generic extended-release metformin	2000s	Reduced XR exclusivity
Current market	2020s	Multi-source generic market

Exact patent expiration dates for legacy Glucophage products are less commercially relevant than the current regulatory status: metformin is available from numerous suppliers, and no active foundational patent provides the brand with market exclusivity.

What patents protect Glucophage?

No active foundational patent is generally viewed as protecting the metformin molecule in the United States. The relevant intellectual-property history involved older composition, formulation, manufacturing, and extended-release technologies.

Potential historical patent categories included:

• Metformin hydrochloride composition and pharmaceutical use.
• Immediate-release tablet formulations.
• Extended-release matrix systems.
• Excipients and release-control technology.
• Manufacturing processes.
• Combination products containing metformin and another antidiabetic agent.

The original metformin molecule and basic therapeutic use are long out of patent protection. Any remaining patent value would have depended on narrow formulation, combination, or process claims rather than ownership of metformin itself.

What formulations are protected by Glucophage patents?

The principal differentiated formulation was Glucophage XR, which used extended-release technology to permit once-daily or less frequent dosing in appropriate patients. Generic manufacturers have obtained approval for extended-release metformin products, eliminating the core commercial barrier to substitution.

Formulation patents can still affect a particular generic manufacturer if they claim a specific release profile, excipient combination, coating, tablet architecture, or manufacturing method. They do not restore exclusivity to the Glucophage brand across the entire metformin market.

What is the Orange Book status of Glucophage?

The FDA Orange Book lists approved drug products and, where applicable, patents and regulatory exclusivity. Glucophage has no current market position comparable to a newly approved single-source medicine with active Orange Book protection.

Immediate-release and extended-release metformin products are available from multiple approved manufacturers. The commercial significance of any residual Orange Book listing would depend on whether it covers a commercially relevant product and whether generic applicants must address it through a Paragraph IV certification.

Because Glucophage is a mature product, the key Orange Book conclusion is practical: generic substitution and multi-source supply have removed the brand’s ability to control the category through patent exclusivity.[3]

Are there Paragraph IV challenges to Glucophage?

Paragraph IV litigation was relevant when generic applicants challenged patents associated with branded metformin products, particularly extended-release formulations. A generic applicant uses a Paragraph IV certification to assert that a listed patent is invalid, unenforceable, or not infringed.

For legacy Glucophage products, any such disputes are historical rather than a current barrier to broad generic supply. The market now contains multiple approved metformin manufacturers, which indicates that the principal patent barriers have been overcome, expired, or become commercially immaterial.

The commercial risk in metformin is therefore not a wave of new Paragraph IV launches. It is continued price compression among existing suppliers.

Which companies compete with Glucophage?

Competition exists at three levels.

Generic metformin manufacturers

The U.S. and international markets include large generic companies and regional manufacturers such as:

• Teva Pharmaceutical Industries.
• Viatris.
• Sandoz.
• Lupin.
• Sun Pharmaceutical Industries.
• Zydus Lifesciences.
• Dr. Reddy's Laboratories.
• Torrent Pharmaceuticals.
• Hikma Pharmaceuticals.
• Several contract manufacturers and local suppliers.

The competitive field varies by country and dosage form. Supplier concentration is usually higher for specific strengths, pack sizes, or extended-release products than for the active ingredient category as a whole.

Branded-generic products

In many markets, metformin is sold under multiple local brands. Branded generics may compete through physician familiarity, distribution, packaging, quality reputation, and fixed-dose combinations. These products can command a modest premium over unbranded generic metformin but generally lack the pricing power of patented therapies.

Newer diabetes drugs

Metformin competes indirectly with:

• Semaglutide and other GLP-1 receptor agonists.
• Tirzepatide.
• Empagliflozin, dapagliflozin, and other SGLT2 inhibitors.
• Sitagliptin and other DPP-4 inhibitors.
• Insulin products.
• Sulfonylureas and thiazolidinediones.

GLP-1 and GIP/GLP-1 therapies are the largest strategic threat to diabetes spending share, not necessarily to metformin prescription volume. Metformin often remains an initial or background therapy while higher-cost medicines are added for glycemic, cardiovascular, renal, or weight-management objectives.

How strong is the Glucophage patent estate?

The current Glucophage patent estate is weak as a platform for exclusivity. Its strengths are clinical familiarity, broad physician adoption, manufacturing scale, and low cost. Its weaknesses are generic substitution, limited differentiation, and the absence of meaningful molecule-level patent protection.

Patent-estate factor	Assessment
Active ingredient protection	Minimal or none
Immediate-release formulation protection	Expired or commercially overcome
Extended-release protection	Generic competition established
Manufacturing barriers	Low to moderate
Regulatory barriers	Low for established generic suppliers
Clinical familiarity	High
Pricing power	Low
Switching risk	High in reimbursed markets
Litigation leverage	Limited

Manufacturing quality remains a practical barrier. Metformin products must meet potency, dissolution, impurity, stability, and manufacturing requirements. The barrier is operational rather than patent-based.

What FDA regulatory issues affect metformin?

The most important recent regulatory event was the FDA investigation into nitrosodimethylamine, or NDMA, contamination in some extended-release metformin products. In 2020, the FDA requested recalls of certain products after testing identified NDMA above acceptable intake limits.[4]

The episode affected specific manufacturers and lots rather than invalidating metformin as a therapy. It created short-term supply disruption, recall costs, testing requirements, and reputational pressure. The FDA advised patients not to stop metformin without consulting a health-care professional because alternative products remained available.[4]

Other regulatory considerations include:

• Renal-function restrictions and dosing requirements.
• Lactic acidosis warnings in high-risk patients.
• Labeling for contrast-imaging procedures.
• Pediatric use.
• Product quality and supply continuity.
• Bioequivalence requirements for generic extended-release tablets.

What licensing deals affected Glucophage?

Glucophage originated outside the United States and reached different markets through corporate ownership, licensing, and distribution arrangements. In the United States, Bristol-Myers Squibb was associated with Glucophage commercialization. Merck and related entities marketed metformin products in other regions, including under the Glucophage name or related brands.

The commercial value of historic licensing arrangements has declined because generic metformin is widely available. Current licensing economics are more relevant to:

• Fixed-dose combinations.
• Modified-release technology.
• Regional branded-generic rights.
• Contract manufacturing.
• Distribution agreements.
• Combination diabetes portfolios.

No licensing structure can recreate molecule-level exclusivity for mature metformin.

What patent litigation affects Glucophage?

There is no widely recognized current U.S. patent dispute that materially restricts access to immediate-release or extended-release generic metformin. Historic litigation centered on generic challenges to branded formulation patents and the timing of generic entry.

The more relevant legal risks now involve:

• Product liability.
• Manufacturing defects.
• Recall-related claims.
• Antitrust or supply-distribution issues.
• ANDA litigation involving newer combination products.
• Patent disputes over metformin combinations rather than metformin alone.

A company assessing a metformin acquisition should focus on regulatory compliance, supply reliability, procurement pricing, and channel concentration rather than expecting a patent-driven litigation premium.

What is the financial trajectory of Glucophage?

Glucophage’s financial trajectory has three phases.

Branded growth phase

Before generic erosion, branded Glucophage benefited from physician adoption, increasing diabetes prevalence, and relatively limited competition. The brand generated value through prescription volume and brand pricing.

Generic erosion phase

Generic entry reduced branded market share and average selling prices. Glucophage XR retained some differentiation through once-daily dosing and patient familiarity, but extended-release generic competition ultimately limited the opportunity.

Mature generic phase

The current market is characterized by high unit demand, low price per tablet, and thin margins. Revenue growth is likely to track volume, price changes, and geographic expansion rather than premium pricing. Any company with exposure to generic metformin is more likely to see stable or modestly growing revenue than pharmaceutical-style blockbuster expansion.

Public financial statements generally do not isolate Glucophage revenue. Bristol-Myers Squibb’s current financial reporting does not present Glucophage as a material standalone growth asset. The brand’s historical revenues should not be used as a proxy for current metformin-market revenue.

What generic launch scenarios exist for Glucophage?

The principal generic launch scenario has already occurred: immediate-release and extended-release metformin are supplied by multiple manufacturers.

Future commercial scenarios are incremental:

Scenario	Probability profile	Market effect
Additional generic entrants	Moderate	Further price pressure
Supplier withdrawal	Possible	Temporary shortages and price volatility
Branded-generic relaunch	Selective	Limited regional premium
New fixed-dose combinations	Ongoing	Higher value per prescription
Reformulated extended-release product	Selective	Possible niche differentiation
Return of molecule-level exclusivity	Not commercially realistic	No material effect expected

A supply disruption could temporarily improve pricing for remaining manufacturers, but the presence of multiple qualified suppliers limits durable pricing expansion.

How does Glucophage compare with newer diabetes drugs?

Attribute	Glucophage/metformin	GLP-1 or GIP/GLP-1 drugs	SGLT2 inhibitors
Market maturity	Mature generic	Patent-protected or recently launched	Mix of protected and generic products
Price	Low	High	Moderate to high
Route	Oral	Mostly injectable, some oral options	Oral
Weight loss	Limited	Substantial for leading agents	Modest
Cardiovascular benefits	Established but less differentiated	Strong for selected agents	Strong for selected agents
Renal benefits	Limited relative differentiation	Product-specific	Strong for selected agents
Patent strength	Weak	Often strong	Varies by product
Revenue growth	Volume-driven	Value- and access-driven	Product-dependent

Metformin remains strategically important as a low-cost foundation therapy. Newer agents capture most of the category’s revenue growth because they offer differentiated outcomes and retain patent protection.

What is the geographic coverage of Glucophage?

Metformin is sold in most major pharmaceutical markets. The Glucophage brand name has different commercial relevance by jurisdiction:

• United States: generic metformin dominates.
• Europe: generic and branded-generic products dominate, with local brand variation.
• India: extensive branded-generic competition.
• China: high-volume domestic generic supply.
• Latin America: mix of originator, branded-generic, and unbranded products.
• Emerging markets: access depends on reimbursement, procurement, and local manufacturing.

Patent and regulatory analysis must be conducted country by country. A formulation patent expired in the United States may not have had the same term, scope, or enforcement history elsewhere.

What revenue exposure remains for manufacturers?

For a manufacturer, metformin is a scale and portfolio product rather than a high-margin innovation asset. Revenue exposure is highest for companies with:

• Large diabetes portfolios.
• Government and hospital contracts.
• Broad retail-pharmacy distribution.
• Local manufacturing advantages.
• Strong active pharmaceutical ingredient sourcing.
• Fixed-dose combination products.

The key variables are volume, tender wins, capacity utilization, raw-material costs, regulatory compliance, and product availability. Price increases are difficult to sustain unless a competitor exits or a shortage develops.

Key Takeaways

• Glucophage is the legacy brand of metformin, while the current market is predominantly generic.
• U.S. market exclusivity ended long ago for immediate-release and extended-release metformin.
• The active ingredient has no meaningful current molecule-level patent protection.
• Formulation and process patents have limited remaining commercial significance because generic products are widely approved.
• No biosimilar pathway applies because metformin is a small-molecule drug, not a biologic.
• Paragraph IV disputes were historically relevant but are not the primary current market risk.
• The 2020 NDMA recalls affected certain metformin products and created temporary supply and compliance pressure.
• Metformin prescription volume should remain resilient as global diabetes prevalence increases.
• Revenue growth is constrained by low prices, generic substitution, and intense supplier competition.
• Newer GLP-1, GIP/GLP-1, and SGLT2 therapies are capturing diabetes spending growth, but metformin remains a common foundational treatment.
• The principal investment risks are price compression, supply interruptions, regulatory quality events, and declining branded relevance.

FAQs About Glucophage Patent and Market Economics

Is Glucophage still a profitable branded drug?

Glucophage is unlikely to have the profitability profile of a protected branded medicine. Most market value has migrated to generic manufacturers, regional branded generics, and combination products.

Does Glucophage have biosimilar competition?

No. Biosimilars apply to biologic products. Metformin is a chemically synthesized small-molecule drug and competes through generic drug approvals.

Can generic metformin replace Glucophage XR?

Approved generic extended-release metformin products can generally substitute for Glucophage XR under applicable pharmacy and regulatory rules. Product-specific substitution depends on jurisdiction, formulation, strength, and local labeling.

Are metformin combination products more valuable than Glucophage?

They can generate higher revenue per prescription because they combine metformin with another active ingredient and may retain formulation or combination patents. Their commercial value depends on the partner drug, patent term, reimbursement, and generic timing.

Is metformin demand declining because of Ozempic and Mounjaro?

Metformin may lose some treatment share in selected patients, particularly where weight loss or cardiovascular and renal outcomes drive prescribing. Global diabetes growth, low cost, and continued use as background therapy support ongoing high volume.

References

1. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178. https://doi.org/10.2337/dc24-S009

2. International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). International Diabetes Federation. https://diabetesatlas.org

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2020). FDA updates and press announcements on NDMA in metformin. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin

5. U.S. Food and Drug Administration. (1994). Glucophage prescribing information. Bristol-Myers Squibb Company.

6. U.S. Food and Drug Administration. (2000). Glucophage XR prescribing information. Bristol-Myers Squibb Company.